A5113511458- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Metastasis and carcinoma case studies
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Colorectal Cancer Treatments and Studies
- Biosimilars and Bioanalytical Methods
- RNA modifications and cancer
- Breast Lesions and Carcinomas
- Allelopathy and phytotoxic interactions
- Chemotherapy-related skin toxicity
- Breast Implant and Reconstruction
- Medical Imaging Techniques and Applications
- Pharmaceutical studies and practices
- Nonmelanoma Skin Cancer Studies
Sun Yat-sen University
2014-2025
Sun Yat-sen University Cancer Center
2009-2024
Eastern Hepatobiliary Surgery Hospital
2024
Second Military Medical University
2024
State Key Laboratory of Oncology in South China
2017-2023
Thoracic Surgery Foundation
2008
•BCBM genomic profiling is similar to that of the PTs: both have high mutation frequencies in TP53 and PIK3CA.•TMB TILs were relatively low BCBMs ∼8% had TMB.•Actionable GAs additional actionable undetected matched samples detected 94% 31% BCBMs. BackgroundBreast cancer brain metastasis (BCBM) a crucial issue treatment breast associated with poor prognosis. Therefore, novel therapeutic targets are urgently needed clinical practice. In this study, we aimed identify potential metastases (BMs)...
BackgroundGastric cancer (GC) is one of the most common clinical malignant tumors worldwide, with high morbidity and mortality. The commonly used tumor-node-metastasis (TNM) staging some biomarkers have a certain value in predicting prognosis GC patients, but they gradually fail to meet demands. Therefore, we aim construct prognostic prediction model for patients.MethodsA total 350 cases were included STAD (Stomach adenocarcinoma) entire cohort TCGA (The Cancer Genome Atlas), including...
•This article provides ESMO recommendations adapted for the treatment of early breast cancer in Asian patients.•It outlines clinical diagnosis, staging, management, and follow-up patients with cancer.•The applicability regarding availability reimbursement practices are described each region.•The aim is to encourage evidence-based medicine facilitate drug registration across different regions Asia. The European Society Medical Oncology (ESMO) Clinical Practice Guidelines were updated...
Standard of care for pts with metastatic PD-L1+ (Combined Positive Score [CPS] ≥10) TNBC is pembro + CT, but prognosis remains poor. Dato-DXd comprises a humanised, anti-TROP2 IgG1 mAb conjugated to potent topoisomerase I (Topo-I) inhibitor via plasma-stable, tetrapeptide-based, tumour-selective cleavable linker. D high-affinity, human that blocks interaction PD-L1 PD-1 and CD80 by binding PD-L1. In the Ph1 TROPION-PanTumor01 study, demonstrated manageable safety profile encouraging efficacy...
In TROPION-Breast01 (NCT05104866), the antibody-drug conjugate Dato-DXd showed improved efficacy and was well tolerated compared with investigator's choice of CT (ICC) in patients (pts) HR+/HER2– BC. Here we report additional safety analyses. Study design previously described; a secondary endpoint. Mouthwash use advised (steroid mouthwash strongly recommended if available), ophthalmologic assessment required per regulatory request at screening every three 21-day cycles. At data cutoff (Jul...
The therapeutic value of mediastinal lymph node dissection (LND) for early-stage non-small cell lung cancer (NSCLC) remains controversial. We conducted a retrospective study to investigate the impact LND on survival in patients with stage I NSCLC.Clinical data NSCLC who were treated surgical resection during period ten years reviewed. categorized into lobectomy (or pneumonectomy) combined or sampling (LNS) according record their operative procedures. Kaplan-Meier method was used analysis....
7563 Background: We evaluate effect of postoperative adjuvant chemotherapy on overall survival after complete resection stage III-N2 non-small-cell lung cancer. Methods: From Jan.1999 to Dec. 2003, a total 150 non-small cell cancer patients randomly received four cycles (NVB25mg/m2, D1,D5 or paclitaxel 175mg/m2, D1 / carboplatin AUC=5, D1) observation operation. Results: The median for the was 879 days, with 1-year rate 81%, 3-year 43%, and 5-year 28%.There significant difference in between...